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Abstract
Background: This study is designed to provide detailed knowledge on cognitive impairment after out-of-hospital
cardiac arrest (OHCA) and its relation to associated factors, and to validate the neurocognitive screening of the
Targeted Hypothermia versus Targeted Normothermia after Out-of-Hospital Cardiac Arrest trial (TTM2-trial), assessing
effectiveness of targeted temperature management after OHCA.
Methods: This longitudinal multi-center clinical study is a sub-study of the TTM2-trial, in which a comprehensive
neuropsychological examination is performed in addition to the main TTM2-trial neurocognitive screening. Approximately
7 and 24months after OHCA, survivors at selected study sites are invited to a standardized assessment, including
performance-based tests of cognition and questionnaires of emotional problems, fatigue, executive function and
insomnia. At 1:1 ratio, a matched control group from a cohort of acute myocardial infarction (MI) patients is recruited to
perform the same assessment. We aim to include 100 patients per group. Potential differences between the OHCA
patients and the MI controls at 7 and 24months will be analyzed with a linear regression, using composite z-scores per
cognitive domain (verbal, visual/constructive, working memory, episodic memory, processing speed, executive functions)
as primary outcome measures. Results from OHCA survivors on the main TTM2-trial neurocognitive screening battery will
be compared with neuropsychological test results at 7months, using sensitivity and specificity analyses.
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Discussion: In this study we collect detailed information on cognitive impairment after OHCA and compare this to a
control group of patients with acute MI. The validation of the TTM2 neurocognitive screening battery could justify its
inclusion in routine follow-up. Our results may have a potential to impact on the design of future follow-up strategies and
interventions after OHCA.
Trial registration: ClinicalTrials.gov, NCT03543371. Registered 1 June 2018
Keywords: Cardiac arrest, Cognitive dysfunction, Neuropsychological tests, Outcome, Cognitive screening
Background
Cardiac arrest is the abrupt loss of cardiac function and cir-
culation, followed by loss of consciousness. Acute myocar-
dial infarction (MI) is the result of acute coronary ischemia
and necrosis. Many out-of-hospital cardiac arrests (OHCA)
are caused by ventricular arrhythmias complicating acute
MI [1]. However, there are many other cardiac and non-
cardiac causes of cardiac arrest. The main difference in out-
come between acute MI and OHCA is related to the circu-
latory standstill and subsequent brain injury in OHCA.
Since mortality and morbidity after successful resuscita-
tion from OHCA is mostly due to brain injury [2], neuro-
logic function is an important outcome measure. More
than 90% of OHCA survivors have been found to have a
favorable neurological outcome [3], when assessed with
the commonly used clinician-based outcome scales such
as the Cerebral Performance Categories Scale [4] or the
modified Rankin Scale [5]. These scales may however miss
important information regarding milder impact on cogni-
tive and emotional functions [6].
From a neuropsychological point of view, cognitive impair-
ment and emotional problems are common post-arrest. Cog-
nitive impairment has been observed in about half of OHCA
survivors [7–9]. A sub-study of the Target Temperature
Management trial reported impairments in memory, execu-
tive functions or processing speed [10]. These cognitive do-
mains are often impaired post-arrest, but also the most
commonly assessed [11]. Others have reported that language
and visual/constructive functions may be affected as well
[12–14]. Brain damage is often diffuse with multiple atrophic
areas due to transient global cerebral ischemia [15, 16].
The exact causes of cognitive impairment post-arrest
are not yet known. An earlier study from our group found
only minor differences between cognition in OHCA survi-
vors and a gender and age-matched group with acute ST-
elevation myocardial infarction (STEMI) without OHCA
after 6 months follow-up [10]. This suggests that cardio-
vascular risk factors such as vascular degeneration, dia-
betes, hypertension, smoking, dyslipidemia, and physical
inactivity may contribute to the cognitive impairment in
both patient groups. However, these findings need to be
corroborated with more sensitive tests. It is also unclear if
the minor between-group cognitive differences that were
detected persist over a longer time frame, or when using
more detailed methods. In this study, we will again use a
group of matched acute MI patients as controls. This
choice of control group will enable us to separate the ef-
fects of the cardiovascular risk factors from cognitive im-
pairment due to hypoxic-ischemic brain injury caused by
the OHCA.
The greatest recovery of cognitive function is usually
seen in the first 3 months post-arrest, but evidence from
several small studies indicates continued improvement
in some functions during at least the first year [17, 18].
There is a lack of follow-up with neuropsychological in-
struments examining several cognitive domains. Earlier
studies on cognition after OHCA have either included a
smaller number of participants (less than 50), or investi-
gated more patients (100–300) with elementary cognitive
assessments or fewer cognitive domains [10, 17, 19].
Cognitive impairment post-arrest correlates with emo-
tional problems [20]. Symptoms of depression have been
found in 14 to 45% of all survivors, anxiety in 13 to 61%,
and posttraumatic stress in 19 to 27% [21]. Fatigue is
closely related to cognitive and emotional function and
has been reported in 69% of survivors [22]. The full rela-
tionship between fatigue and cognitive impairment,
emotional problems and insomnia has yet not been in-
vestigated in OHCA survivors.
A cognitive and emotional screening post-arrest is rec-
ommended [23, 24] and could identify patients with poten-
tial sequelae, thus offering support, rehabilitation and if
needed a more extensive assessment. Ideally, a follow-up
screening battery should have a low threshold and high
sensitivity so that even a slight impairment can be detected
for further interventions, such as a detailed neuro-
psychological evaluation. The Targeted Hypothermia
versus Targeted Normothermia after Out-of-Hospital
Cardiac Arrest trial (TTM2-trial) is an international,
multicenter, randomized trial in which a target
temperature of 33 °C after OHCA will be compared
with a strategy to maintain normothermia and early
treatment of fever (≥37.8 °C) during the first 40 h after
arrest [25]. The trial will randomize 1900 patients and
includes a brief neurocognitive screening of survivors at
6 and 24 months.
This sub-study of the TTM2-trial aims, using a compre-
hensive neuropsychological test battery, to provide detailed
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and longitudinal information on cognitive impairment in
OHCA survivors in comparison to a control group with acute
MI, and the associated factors emotional problems, fatigue,
insomnia, and vascular cognitive decline. In addition, this
study aims to validate the main TTM2-trial neurocognitive
screening, which could be suitable to include in routine
follow-up if showing sound psychometric properties.
Hypotheses
 OHCA survivors will perform significantly worse on
neuropsychological tests of cognition compared to a
matched cohort of acute MI patients without
cardiac arrest.
 The neurocognitive screening used in the main
TTM2-trial will with high sensitivity and adequate
specificity identify OHCA survivors with cognitive
impairment at 7 months post-arrest.
Methods
Study design
This sub-study of the TTM2-trial is a prospective non-
intervention multi-center clinical study, in which selected
sites participate.
Participants
Inclusion and exclusion criteria [25] are listed in Table 1.
A control group from a cohort of patients with con-
firmed and treated acute MI who underwent coronary
angiography but without occurrence of cardiac arrest will
be recruited at 1:1 ratio. Patients with STEMI and Non-
STEMI are eligible as controls. Exclusion criteria for the
MI-cohort are the same as for OHCA survivors.
No sample size calculation was performed due to a lack
of earlier studies comparing OHCA and MI survivors by
using the tests in this study. Instead, our aim is to include
a convenience sample of 100 patients per group at 7
months after the event.
Table 1 Inclusion and exclusion criteria for the TTM2 neuropsychological sub-study
Inclusion
criteria
Main
TTM2-
trial
TTM2 Neuropsychological
sub-study OHCA patients
TTM2 Neuropsychological
sub-study MI patients
OHCA of a presumed cardiac or unknown cause X X
Sustained ROSC during intensive care – defined as 20 min
with signs of circulation without the need for chest
compressions
X X
Unconsciousness – defined as not being able to obey
verbal commands (FOUR-score motor response of < 4)
and no verbal response to pain after sustained ROSC
X X
Inclusion within 180 min of ROSC X X
During intensive care at admission – eligible for intensive
care without restrictions or limitations
X X
Acute MI with performed coronary angiography X
Exclusion
criteria
Temperature on admission < 30 °C X X
On ECMO prior to return of spontaneous circulation X X
Obvious or suspected pregnancy X X
Intracranial bleeding X X
Severe COPD with long-term home oxygen therapy X X
Age < 18 X X X
Age ≥ 80 X X
Clinical dementia diagnosis before the event X X
Inability to speak the local language well enough to
complete the assessment without assistance from
an interpreter
X X
Inability to meet for a face-to-face examination X X
Active drug abuse X X
Clinical Frailty Scale Index ≥8, indicating very severe
frailty [26]
X X
Cardiac arrest before or in connection with MI X
OHCA out-of-hospital cardiac arrest; MI myocardial infarction; ROSC return of spontaneous circulation; ECMO extracorporeal membrane oxygenation; COPD chronic
obstructive pulmonary disease
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Ethical approval, informed consent and trial registration
Ethical applications for the TTM2-trial and this sub-study
were approved by all participating countries. All eligible
patients at participating sites will receive written and oral
information and be asked to take part in the neuropsycho-
logical sub-study. Patients will be asked to sign a written
informed consent. The TTM2-trial and this sub-study are
registered at ClinicalTrials.gov (NCT02908308 and
NCT03543371).
Procedure
The main TTM2-trial follow-up at 6 months includes a
neurocognitive screening [27], which consists of the
performance-based instruments Montreal Cognitive As-
sessment (MoCA) [28] and Symbol Digit Modalities Test
(SDMT) [29], the patient-reported Two Simple Ques-
tions (TSQ) [30, 31] and the observer-report Informant
Questionnaire on Cognitive Decline in the Elderly-
Cardiac Arrest (IQCODE-CA) [32, 33].
During the 6-month follow-up of the TTM2-trial, OHCA
survivors at participating sites will be invited to partake in
this sub-study. At a separate face-to-face appointment at 7
months (preferably within 28 days after regular follow-up)
specific to this sub-study, a standardized neuropsycho-
logical battery will be administered. The battery comprises
performance-based tests of major cognitive domains; ver-
bal, visual/constructive, working memory, episodic mem-
ory, processing speed, and executive functions. Instruments
will be administered according to guidelines in each man-
ual, including criteria for discontinuing single instruments.
The examination will be completed in one single session
per follow-up, in a predefined order, and requires approxi-
mately 65–85min with small breaks allowed. Neuropsy-
chologists, psychologists, assistant clinical psychologists,
and psychology students (under supervision of a psycholo-
gist) will administer the tests after participating in an intro-
ductory/training session. Patients and informants are asked
to fill out four questionnaires of emotional problems, fa-
tigue, executive dysfunction and insomnia prior to, or after
the visit. Three of the questionnaires are self-report mea-
sures and will be returned by the patient. The fourth ques-
tionnaire is to be completed by an informant, i.e. a relative
or close friend. This questionnaire could be returned in a
pre-paid envelope by regular mail, in order to maintain the
privacy of the informant.
The same neuropsychological test battery will be re-
peated 24months post-arrest to investigate to what ex-
tent the long-term cognitive outcome of the survivors is
accurately predicted by the 7 months examination.
For each participating OHCA-survivor a MI control
patient will be recruited per mail and telephone and
assessed at one participating site per country (Fig. 1).
The MI controls are matched according to the following
matching criteria in a descending order: 1) date of
cardiac event (all MI within a time frame of ±4 weeks of
the CA are accepted); 2) sex; 3) age (best match). For MI
control patients, descriptive background information
and information on cardiovascular risk factors will be
collected through objective measures and structured
interview, while the corresponding information for the
OHCA survivors will be collected during the regular
TTM2 follow-up when applicable (Table 2).
The meeting is preferably performed in a clinical set-
ting, but alternative settings could be considered such as
visiting the patient’s place of residence.
Study timeline
The TTM2-trial started on November 18, 2017. The
current sub-study started on July 13, 2018. Sites in
Sweden, the United Kingdom and Denmark are recruiting.
We estimate that the last patients are recruited in 2020,
with the final longitudinal follow-up completed 2022.
Study organization
This is an academically initiated study led by researchers
at Center for Cardiac Arrest at Lund University.
The study is performed in cooperation with the TTM2
sub-study of Physical Activity After Cardiac Arrest
(NCT03543332). If patients choose to participate in this
parallel sub-study, the appointments are merged.
Instruments
An overview of the neuropsychological test battery, in-
cluding reliability coefficients, is found in Table 3, with
scores used for computing composite z-scores per cogni-
tive domain appearing in bold. The questionnaires are
presented in Table 4.
Verbal domain
The Vocabulary subtest from the Wechsler Adult
Intelligence Scale – Fourth Edition (WAIS-IV) [39] as-
sesses knowledge of words, abilities to verbalize concepts
and retrieve information from the semantic memory.
The Letter Fluency condition of the Verbal Fluency sub-
test from the Delis-Kaplan Executive Function System (D-
KEFS) [40] assesses oral productions of words beginning
with a specified letter. The Category Fluency condition as-
sesses oral production of words within a designated cat-
egory. Letter Fluency is proposed to put greater emphasis
on executive aspects such as attention allocation and stra-
tegic organization than Category Fluency [41]. However,
both phonemic and semantic fluency has been reported to
load exclusively on a language factor [42].
Visual/constructive domain
The Block Design subtest from the WAIS-IV [39] as-
sesses visuospatial organization. Bonus points are given
for a quick, error-free performance. It is relatively free
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from cultural and educational bias, and is generally sen-
sitive to any kind of cerebral dysfunction [43].
The Matrix Reasoning subtest from the WAIS-IV [39]
is a test of non-verbal abstract reasoning and perceptual
organization.
Working memory domain
The Digits Forward condition of the Digit Span subtest
from the WAIS-IV [39] emphasizes attention efficiency
and auditory short-term memory. Digits Backwards em-
phasizes aspects of working memory, as does Digit Se-
quencing. The latter conditions are more difficult and
rather sensitive to brain injury or deterioration [44].
The Spatial Span subtest from the Wechsler Memory
Scale – Third Edition (WMS-III) [45] tests visuospatial
working memory. The Backward condition is more sen-
sitive to cognitive impairment than the Forward condi-
tion, requiring more complex working memory and
visual manipulation skills [46].
Episodic memory domain
The Rey Auditory Verbal Learning Test (RAVLT) [47] is
a test of verbal learning and verbal episodic memory, by
immediate recall in five trials, delayed recall and recogni-
tion of a word list.
In the Logical Memory subtest from the WMS-III
[45], the subject is asked to recall two stories immedi-
ately and delayed.
The Brief Visuospatial Memory Test-Revised (BVMT-R)
[48] measures visual learning and visual episodic memory
by immediate recall in multiple trials, delayed recall and
recognition. There are six different test forms of the
BVMT-R with equivalent psychometric properties.
Processing speed domain
The Trail Making Test (TMT) [49, 50] subtask A is a
test of visual scanning with a motoric component. The
TMT is vulnerable to brain dysfunction in general [43].
The Color-Word Interference Test (CWIT) from the
D-KEFS [40] originates from the classic Stroop paradigm
[51]. In its first two conditions, the CWIT measures pro-
cessing speed.
Executive functions domain
The TMT subtask B measures executive aspects such as
cognitive flexibility in addition to processing speed [49, 50].
The third condition of the CWIT measures executive
functions such as inhibition of a dominant and automatic
verbal response, and sustained selective attention [40].
Questionnaires
The Hospital Anxiety and Depression Scale (HADS) is a
screening for symptoms of anxiety and depression by self-
report [52]. The questionnaire consists of seven items for
an anxiety subscale and seven items for a depression sub-
scale. Each item is scored on a four-point scale, with re-
sponses totaled to obtain two subscale scores. A cut-score
Fig. 1 Flowchart of TTM2 neuropsychological sub-study inclusion. TTM2, Targeted Hypothermia versus Targeted Normothermia after Out-of-
Hospital Cardiac Arrest trial
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of ≥8 per subscale is considered to have a good balance
between sensitivity and specificity, with most studies con-
firming the two-factor structure [53].
The Dysexecutive Questionnaire (DEX) from the Be-
havioral Assessment of the Dysexecutive Syndrome
(BADS) [54] is designed to measure dysexecutive symp-
toms in everyday situations such as planning problems,
distractibility and lack of insight. Items are rated on a
five-point scale from zero to four, with higher scores
representing greater problem severity. One version of
the questionnaire should be completed by the subject
(DEX-Self) and another version by an informant (DEX-
Other). Discrepancies between the DEX-Self and DEX-
Other are indicative of impaired insight [54]. A recent
study using exploratory factor analysis on a large clinical
and non-clinical sample resulted in confirmation of a
one-factor solution for the DEX [55].
The Multidimensional Fatigue Inventory (MFI-20)
measures fatigue in the past week in five dimensions:
General fatigue, Physical fatigue, Reduced activity, Re-
duced motivation, and Mental fatigue [56, 57]. Items are
rated on a five-point Likert scale, with an optional total
score obtained by adding up the subscale scores. Higher
scores indicate a higher degree of fatigue.
The Minimal Insomnia Symptom Scale (MISS) is an
insomnia-screening questionnaire [58]. Items are rated
on a five-point scale, yielding a total score ranging from
0 to 12 with higher scores indicating more insomnia.
Rasch modeling has shown that a cut-score of ≥6 seems
to be suited for adults and elderly when identifying pres-
ence of insomnia, although clinical criteria recently has
been revised [59].
Statistical analyses
Raw scores from all neuropsychological instruments will
be converted to standardized z-scores in accordance
with normative sample data (based on age and, when ap-
plicable, education) for each test. The z-scores will be
adjusted for level of education and sex as covariates,
when not already adjusted for in the z-score transform-
ation. Test data will be grouped based on the six main
cognitive domains measured by the tests (verbal, visual/
constructive, working memory, episodic memory, pro-
cessing speed, executive function). A composite z-score
will be computed for each cognitive domain in accord-
ance with Table 3, which also indicates the test scores
used for composite z-scores computation. Parametric
tests will be used for all analyses because of the z-score
standardization and, in accordance with the central limit
theorem, a large number of participants per group. A p
of <.05 is considered significant for all analyses.
The first hypothesis will be analyzed with a linear re-
gression adjusting for level of education and sex when
examining the outcome at 7 months. These results will
be reported separately. The analyses will be repeated at
24 months. Composite z-scores per cognitive domain are
used as primary outcome measures.
The second hypothesis will be analyzed with a
comparison of the OHCA survivors’ results on the
neurocognitive screening and the detailed neuro-
psychological test battery at 7 months’ time. This will
be performed by a sensitivity and specificity analysis
emphasizing high sensitivity and adequate specificity,
including true and false positive rates. Here, patients
will be considered to have a cognitive impairment if
they meet any of the following criteria on the neuro-
psychological tests: 1) an impaired composite z-score
defined as z ≤ − 1.65 in at least one cognitive domain;
2) z ≤ − 1.65 in at least two scores used for cognitive
domain calculation as per Table 3, independent of
their domain classification. The proportion of OHCA
survivors with impairments on neuropsychological
tests will be compared with the proportion of OHCA
Table 2 Descriptive background data used in the TTM2
neuropsychological sub-study
Variable
Age
Level of education
Living situation
Working status before and post event
Results of the MoCA
Results of the SDMT
Results of the TSQ
Results of the IQCODE-CA
Current smoking
Current diabetes
Total cholesterol
HDL cholesterol
Systolic blood pressure
HBA1c
Length
Weight
Any current pharmaceutical treatment for hypercholesterolemia
Any current pharmaceutical treatment for diabetes
Any current pharmaceutical treatment for high blood pressure
Any current pharmaceutical treatment for agitation/anxiety#
Any current pharmaceutical treatment for depression#
Any current pharmaceutical treatment for insomnia#
The “#” indicates the background data which are not available through the
main TTM2-trial follow-up and exclusively collected for this sub-study
MoCA Montreal Cognitive Assessment; SDMT Symbol Digit Modalities Test; TSQ
Two Simple Questions; IQCODE-CA Informant Questionnaire on Cognitive
Decline in the Elderly-Cardiac Arrest; HDL high-density lipoprotein
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survivors with indicated cognitive impairment on the neuro-
cognitive screening, by: 1) performance-based instruments
(MoCA, SDMT); 2) self and informant-report instruments
(TSQ question 2, IQCODE-CA); 3) all four instruments to-
gether. As high sensitivity is of importance for a screening,
just one score below cut-off on any screening instrument will
indicate possible cognitive impairment. Cut-scores for
indicated impairment will be < 26 on the MoCA, z ≤− 1 on
the SDMT, ≥3.08 on the IQCODE-CA and the answer “no”
to question 2 at the TSQ.
An explorative approach will be used to analyze changes
in OHCA survivors’ cognition and emotional problems,
fatigue, insomnia, and cardiovascular risk factors from 7
to 24months.
Table 3 Tests and scores used in the TTM2 neuropsychological sub-study, grouped by cognitive domain
Cognitive
domain
Cognitive functions Test Scores Test-retest reliability Administration
order
Verbal • Verbal comprehension
• Concept verbalization
• Semantic memory retrieval
WAIS-IV
Vocabulary
Total score High (.89) 5
• Phonemic fluency
• Semantic memory
retrieval
• Working memory
capacity
• Processing speed
D-KEFS
Verbal
Fluency
Letter fluency score, category
fluency score, category switching
score, category switching accuracy,
first interval, second interval, third
interval, fourth interval,
set-loss errors, repetition errors
Letter fluency: High (.80)
Category fluency: Adequate
(.79)
13
Visual/
constructive
• Visuospatial organization
• Visuomotor speed
WAIS-IV
Block
Design
Total score, no time bonus score High (.80) 2
• Non-verbal abstract
reasoning
• Perceptual organization
WAIS-IV
Matrix
Reasoning
Total score Adequate (.74) 4
Working
memory
• Verbal short-term
working memory
• Aspects of auditory attentional capacity
WAIS-IV
Digit Span
Total score, digit span forwards score,
digit span forwards longest, digit span
backwards score, digit span backwards
longest, digit span sequencing score,
digit span sequencing longest
Entire subtest: High (.83)
Sub-conditions: Adequate
(.71–.77)
10
• Spatial working memory WMS-III
Spatial Span
Total score, spatial span forward, spatial
span backward
Adequate (.71) 3
Episodic
memory
• Verbal episodic list
memory
• Attention
• Verbal recognition
memory
RAVLT Total recall, delayed recall, delayed
recognition, trial 1, trial 2, trial 3, trial
4, trial 5, trial 6, trial 7
Total and delayed recall:
Adequate to high (.74–.88)
Other trials: Lower [34]
7, 12
• Verbal episodic memory
of prose passages
• Verbal learning
WMS-III
Logical
Memory
Total score I, total score II Adequate (.76–.77) 1, 6
• Visual episodic memory
• Visual learning
• Visual recognition memory
BVMT-R Total recall, delayed recall, recognition
discrimination index, trial 1, trial 2, trial
3, learning, percent retained, recognition
hits, recognition false alarms
Total recall: High (.80)
Other trials: Lower
11, 16
Processing
speed
• Visuomotor processing speed
• Attention
TMT A Score Varies but mostly adequate,
negligible practice effects
over longer retest intervals
[35]
8
• Word naming speed
• Color naming speed
D-KEFS
Color Word
Interference
Test
Color naming, word reading Color naming: Adequate
(.76)
Word reading: Marginal
(.62)
14
Executive
functions
• Cognitive flexibility
• Working memory
• Visuomotor processing speed
TMT B Score As TMT A above 9
• Inhibition of a dominant and
automatic verbal response
• Sustained selective attention
D-KEFS
Color Word
Interference
Test
Inhibition, inhibition total errors Adequate (.76) 15
WAIS-IV Wechsler Adult Intelligence Scale – Fourth Edition; D-KEFS Delis-Kaplan Executive Function System; WMS-III Wechsler Memory Scale – Third
Edition; RAVLT Rey Auditory Verbal Learning Test; BVMT-R Brief Visuospatial Memory Test-Revised; TMT Trail Making Test
Note: Scores used for computing composite z-scores per cognitive domain appear in bold
Blennow Nordström et al. BMC Cardiovascular Disorders          (2020) 20:439 Page 7 of 11
Missing data will be described and categorized as
missing at random and missing not at random.
Discussion
This neuropsychological sub-study of the TTM2-trial is
a prospective, longitudinal multi-center clinical study. It
is designed to provide detailed knowledge on cognition
after cardiac arrest and its relation to emotional prob-
lems, fatigue, insomnia, and cardiovascular risk factors.
This will provide valuable information as the number of
survivors with cognitive impairment is still unclear, and
mainly based on results using relatively crude instru-
ments. Survivors will be followed longitudinally until 24
months post-arrest, which has not been done in other
studies to date with a corresponding level of detail.
Another aim of this study is to compare patients with
and without OHCA. Rather than a group of healthy con-
trols, we have chosen to include a MI cohort as controls,
similar to an earlier study from our group [10]. The de-
tailed neuropsychological profile could be of use when tai-
loring future domain specific rehabilitation interventions
for both patient groups. The matched MI controls in this
study are recruited in the same country as the OHCA sur-
vivors in an effort to bridge any potential differences in
demographics and rehabilitation between countries.
The neuropsychological test battery has been designed to
provide detailed information about the cognitive function
of the patients, while still being feasible to perform in one
single session. A total of six cognitive domains are assessed,
with a minimum of two tests per cognitive domain to re-
duce measurement errors. The tests comprising one cogni-
tive domain are intended to measure the same overall
cognitive function but different sub-components thereof,
which enable analyses of specific test results and functions.
The instruments were selected to represent a range of cog-
nitive, behavioral and emotional functions. They are used
in clinical practice as well as in research, and the majority
of the instruments have previously been used in OHCA
studies. All of the neuropsychological tests and most of the
questionnaires have sound psychometric norms available.
The results of this study will have potential impact on
the planning of future interventions. By validating the
commonly used instruments in the neurocognitive
screening of the TTM2-trial with neuropsychological in-
struments, the screening could be sufficient to serve as a
model for future OHCA follow-up. Screening instru-
ments with good validity enables the identification of pa-
tients in need of more detailed neuropsychological
examination, follow-up and rehabilitation.
In addition to the follow-up assessments, the TTM2
population will be well investigated in the acute phase.
This includes measures of electroencephalography, cere-
bral imaging, clinical neurological examination, and bio-
markers in serum. Adding the detailed neuropsychological
assessment of this study to the analyses, we will be able to
investigate the importance of the acute brain injury and
the chronic degenerative process post-arrest for neuro-
psychological functioning over time.
We have chosen to perform the sub-study specific neuro-
psychological assessment as a separate appointment, rather
than at the same time as the regular TTM2 follow-up. This
is due to fatigue being a common symptom after OHCA
and acquired brain injury in general. Patient weariness and
reduced vigilance thus could have implications for neuro-
psychological test performance [60]. Potential participants,
especially those living far away from the study sites, could
be more unwilling to partake as a result of this study de-
sign. To improve the inclusion ratio and the generalizability
of the results, patients are offered a travel reimbursement
or that the examination is performed in e.g. the patient’s
place of residence.
There is no consensus on how to report cognitive decline
in neuropsychological studies. Educational duration is posi-
tively correlated with premorbid intellectual capacity [61].
Table 4 Questionnaires filled out by the patient or the informant
Focus Questionnaire Respondent Number of
questions
Test-retest reliability
Depression and anxiety symptom
screening
HADS Patient 14 In an acute myocardial infarction sample:
Acceptable [36]
Dysexecutive function BADS DEX Self Patient 20 In an acquired brain injury sample: High
(.88) and marginal for informants (.60) [37]
Dysexecutive function BADS DEX
Other
Informant 20 In an acquired brain injury sample: Marginal for
informants (.60) [37]
Fatigue; general fatigue, physical fatigue,
reduced activity, reduced motivation and
mental fatigue
MFI-20 Patient 20 Adequate (.76), somewhat lower for the
subscale scores [38]
Insomnia screening MISS Patient 3 Unknown
HADS Hospital Anxiety and Depression Scale; BADS DEX Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire; MFI-20
Multidimensional Fatigue Inventory; MISS Minimal Insomnia Symptom Scale
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Striving for high specificity, especially in the neuropsycho-
logical test battery, we adjust for level of education in our
main outcome measures. When comparing the results on
the neurocognitive screening with the detailed neuro-
psychological test battery, the chosen cut-score of z ≤ − 1.65
was inspired by a similar OHCA study [12].
We have refrained from pre-specified comparisons of
the neuropsychological function between the 33 °C and
normothermia treatment arms. Differences in outcome
between the temperature groups will primarily be inves-
tigated within the main TTM2-trial with a larger num-
ber of participants [27].
As for limitations, the TTM2-trial includes OHCA pa-
tients with presumed cardiac cause, however a substantial
portion of the patients may have a non-cardiac cause. Al-
though an exclusion of such patients would be possible in
this sub-study, recruiting at 7months post-arrest, we have
refrained from this possibility because one of our aims is to
validate the main TTM2-trial neurocognitive screening.
Since all our MI controls will have a coronary disease, this
will cause a discrepancy in our background variables. Still, a
similar matching was performed in another study, with
relatively equivalent cardiovascular risk factors between
groups [10]. Another limitation is possible selection bias,
i.e. that those with excellent recovery may be more likely to
say yes to being part of the study, skewing the data in a
positive way. These tendencies have been observed in other
studies [10, 12, 17]. On the other hand, we have informa-
tion from the main TTM2-trial on the patients declining to
participate in this sub-study, facilitating analyses of missing
data. Furthermore, the number of studies comparing
neuropsychological outcome after OHCA and MI are few,
and the tests used in this study are more sensitive than in
most earlier studies. Thereby no sample size calculation
could be performed for this study; however, the detailed
and sensitive information will enable us to explore hypoth-
eses generating trends in a large sample of cardiac arrest
survivors and controls.
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